Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults

Cataldo Patruno, Luca Stingeni, Katharina Hansel, Silvia Mariel Ferrucci, Simona Tavecchio, Gabriella Fabbrocini, Steven Paul Nisticò, Caterina Foti, Serena De Prezzo, Maddalena Napolitano

Research output: Contribution to journalArticle

Abstract

Nummular eczema (NE) is currently considered as one of the clinical phenotypes of atopic dermatitis (AD) of the adult. In this multicentre study, 30 adult patients (age ≥ 18 years) affected with nummular-like AD were treated with dupilumab, a monoclonal antibody against the receptor for interleukin(IL)-4 and IL-13. The evaluation of the results after 16 weeks of treatment showed a significant improvement of the disease, as demonstrated by reduction in Eczema Area Severity Score (EASI), visual analogue score (VAS) of pruritus, and Dermatology Life Quality Index (DLQI) scores. Conjunctivitis in one patient was the only side effect. In conclusion, dupilumab seems to be an effective and safe treatment in NE phenotype of AD of the adult.

Original languageEnglish
Article numbere13290
JournalDermatologic Therapy
Volume33
Issue number3
DOIs
Publication statusAccepted/In press - Jan 1 2020

Keywords

  • adult atopic dermatitis
  • dupilumab
  • nummular eczema
  • phenotype

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults'. Together they form a unique fingerprint.

  • Cite this

    Patruno, C., Stingeni, L., Hansel, K., Ferrucci, S. M., Tavecchio, S., Fabbrocini, G., Nisticò, S. P., Foti, C., De Prezzo, S., & Napolitano, M. (Accepted/In press). Effectiveness of dupilumab for the treatment of nummular eczema phenotype of atopic dermatitis in adults. Dermatologic Therapy, 33(3), [e13290]. https://doi.org/10.1111/dth.13290